Abstract: A light emitting diode (LED) structure that includes a stent substrate; and a circuit having a plurality of contact pads arranged along a length of the stent substrate. The structure further includes a plurality of light emitting diode (LED) chips, wherein each light emitting diode chip in the plurality of chips is engaged to a set of contact pads along the length of the metal stent substrate. A continuous phosphor layer is present overlying the plurality of light emitting diode (LED) chips, the continuous phosphor layer including first portions that are in direct contact with at least a light transmission surface of the light emitting diode (LED) chips and second portions that bridge across the space separating adjacently positioned light emitting diode. An encapsulant present over the continuous phosphor layer that is covering at least the light emitting diode chips.

Abstract: A lighting structure including a light engine contained within a housing, there the housing is comprised of a fire-retardant material. The lighting structure may further include a fire sensor assembly mounted within the housing, the fire sensor assembly comprising a sensor and a message sending device.

Abstract: The present invention relates to the field of pharmaceutical formulations. Disclosed are a composition containing Lumateperone active ingredients, and a long-acting sustained-release formulation and a preparation method therefor. A composition containing Lumateperone active ingredients capable of achieving long-acting sustained release is obtained by means of a specific definition on medicinal polymer auxiliary materials; and preparation process conditions are further controlled to obtain a long-acting sustained-release formulation containing Lumateperone active ingredients, so that the sustained release of Lumateperone is implemented in one week to two months, and compared with general formulations (for example: capsules), the compliance of patients can be effectively improved; and clinical requirements of stable drug release are satisfied while the drug safety and effectiveness are ensured.

Abstract: This application relates to container storage management methods and apparatuses. An example method is used to manage a containerized application. The containerized application is deployed in a first container cluster. The first container cluster includes a plurality of nodes. The method includes collecting a plurality of pieces of storage association information from the plurality of nodes. The storage association information is information related to data storage of the containerized application. The method further includes summarizing the plurality of pieces of storage association information to obtain a storage topology of the containerized application. The storage topology of the containerized application includes an association between an element of the containerized application and a physical storage location of the containerized application.

Abstract: Provided are a point cloud encoding method and decoding method, and an encoder and a decoder. The encoding method includes: processing attribute information of a target point in a point cloud, so as to obtain a predicted residual of the attribute information of the target point; quantizing the predicted residual on the basis of a quantized weight of the target point and a quantized stride of the target point, so as to obtain a quantized residual of the attribute information of the target point, wherein the quantized weight of the target point is the weight used when weighting the quantized stride of the target point; and encoding the quantized residual, so as to obtain a code stream.

Abstract: A point cloud decoding method is applied to a decoder and includes the following. Reconstructed attribute information of occupied neighbouring nodes of a current node and reconstructed attribute information of occupied same-level neighbouring child nodes of a child node of the current node are determined. An attribute prediction value of the child node of the current node is determined according to the reconstructed attribute information of the occupied neighbouring nodes and the reconstructed attribute information of the occupied same-level neighbouring child nodes of the child node of the current node. A first transformed coefficient is determined by performing region adaptive hierarchal transform (RAHT) on the attribute prediction value, and reconstructed attribute information of the child node of the current node is determined according to the first transformed coefficient.

Abstract: Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of a BCL-2 inhibitor; and optionally, a therapeutically effective amount of at least one other antineoplastic agent. Also disclosed are methods for treating a subject who has been diagnosed with a hematopoietic disorder using such combinations. Compounds are represented by Formula (I) as follows: wherein the variables are defined herein.

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia.

Abstract: Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows: wherein the variables are defined herein.

Abstract: The present invention discloses a polymerizable compound, a liquid crystal composition comprising the polymerizable compound, and a liquid crystal display device. The polymerizable compound is a compound represented by the following formula I, wherein Sp represents a single bond or a C1-C5 linear, branched or cyclic alkyl group, and the Sp groups are not both single bonds, wherein any one or more non-adjacent —CH2— can be replaced by —O—, —S—, —CO—, —CH2O—, —OCH2—, —COO—, —OOC—, or an acrylate group in such a manner that O- or S-atoms are not directly connected with each other, one or more H atoms can be independently replaced by F, C1, or G3, and at least one H atom is replaced by G3; G3 represents a C1-C7 tertiary alcohol structure; and X represents —CH2—, —O—, or —S—. In particular, the polymerizable compound has the advantages of good diffusivity, high stability of the formed polymer, and low residue after a UV process.

Abstract: A method performed by a network node comprising an active antenna system in a telecommunication network. The network node can identify a plurality of available branches from a plurality of branches of the active antenna system for supporting a narrowband signal. The network node can further map at least two available branches from the plurality of available branches to at least one subcarrier of a plurality of subcarriers from the narrowband signal, wherein each of the at least two available branches are mapped to different sets of subcarriers from the plurality of subcarriers.

Abstract: An interface display method and an electronic device are provided. The method includes: performing screen-on interception in response to a screen wakeup operation performed by a user on an electronic device, to prevent a screen from being lit up; drawing an interface adapted to a screen orientation; and after the interface is drawn, disabling screen-on interception, and displaying the interface based on the screen orientation. The electronic device may collect and report data in real time through a sensor, and calculate a current screen orientation in real time, so that the drawn interface adapts to the current screen orientation.

Abstract: The present disclosure relates to a crystal form of a neurokinin-1 antagonist prodrug compound. Specifically, the present disclosure relates to a novel crystal form of a compound represented by formula I and a preparation method. The novel crystal form of the present disclosure has a good physicochemical property and better facilitates clinical treatment.

Abstract: Aspects of the present disclosure describe a method including predicting a first set of ansatz terms and a first plurality of amplitudes associated with the first set of ansatz terms; minimizing energy of the system based on the first set of ansatz terms and the first plurality of amplitudes; computing perturbative corrections using one or more ansatz wavefunctions; determining whether energy of the system converges; and predicting, in response to determining that the energy of the system does not converge, a second set of ansatz terms and a second plurality of amplitudes associated with the second set of ansatz terms.

Abstract: An encoding method includes: a first reference block of a current block is determined; motion compensation enhancement is performed on the first reference block to obtain at least one second reference block; motion information of the current block is determined according to the at least one second reference block; the current block is encoded according to the motion information; and a first syntax element identification information is setted, wherein the first syntax element identification information is for indicating whether to use a motion compensation enhancement processing mode for the current block; and a value of the first syntax element identification information is encoded, and encoded bits are signalled.

Abstract: Provided herein is a nucleic acid extraction and the structure of a reaction chamber is improved such that a piston, a reaction chamber and a magnetic rod are independent of one another, magnetic beads are more concentrated, more sufficient adsorption, washing and elution are achieved, dead corners are eliminated, when the nucleic acid extraction and amplification device is used to perform nucleic acid extraction and amplification. The sensitivity and accuracy of nucleic acid detection can be further improved, and missing and wrong detection can be avoided.

Abstract: A lighting fixture with a foldable lampshade comprises a lampshade and a light source assembly; the lampshade includes a foldable semi-rigid sheet material, on which crease lines for guiding folding are provided; edge areas of the lampshade abut and fit against each other in unfolded state; the lighting fixture further includes a connecting buckle, which includes a first engaging member and a second engaging member respectively disposed on two edge areas; the first engaging member and second engaging member are mutually matched and clamped to lock and fix the connecting buckle when the two edge areas abut against each other; the light source assembly includes a plurality of LED beads disposed inside the lampshade. By adopting the semi-rigid sheet material, the lampshade can maintain a certain degree of flexibility when folded, facilitating storage and transportation, and can maintain sufficient structural strength after unfolding to avoid shape deformation or instability.

Abstract: An electrostatic chuck (ESC) undercoating system includes a memory and a controller. The memory stores an undercoat application. The controller configured to execute the undercoat application to: determine undercoat parameters; perform a full clean process to remove undercoat deposits in processing chamber of substrate processing system; and based on the undercoat parameters, perform one or more deposition processes to deposit one or more undercoat layers on the ESC to provide an overall undercoat layer having an overall thickness between 7-15 ?m, the one or more undercoat layers providing protection of the ESC during subsequent deposition processing of a substrate on the ESC.